Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
about
Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomographySome implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonistsEfficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathwaysHow Does the Brain Implement Adaptive Decision Making to Eat?Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessorsIdentification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.Fitting the complexity of GPCRs modulation into simple hypotheses of ligand design.Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptorLigand-binding domain subregions contributing to bimodal agonism in cyclic nucleotide-gated channelsIdentification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptorOpioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependenceThe design, synthesis and pharmacological characterization of novel β₂-adrenoceptor antagonists.Tonic regulation of GABAergic synaptic activity on vasopressin neurones by cannabinoids.Evidence for constitutively-active adenosine receptors at mammalian motor nerve endingsCannabinoid receptors: nomenclature and pharmacological principlesIn vivo pharmacological resultant analysis reveals noncompetitive interactions between opioid antagonists in the rat tail-withdrawal assay.Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists.Maturational alterations in constitutive activity of medial prefrontal cortex kappa-opioid receptors in Wistar ratsGenetic variation in G-protein-coupled receptors--consequences for G-protein-coupled receptors as drug targets.Synthesis and structure-affinity relationships of selective high-affinity 5-HT(4) receptor antagonists: application to the design of new potential single photon emission computed tomography tracers.Muscarinic receptor agonists and antagonists: effects on cancerMechanism of N-terminal modulation of activity at the melanocortin-4 receptor GPCR.Pharmacological onomastics: what's in a name?Molecular Pharmacology of δ-Opioid Receptors.Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics.Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.Label-free optical biosensor: a tool for G protein-coupled receptors pharmacology profiling and inverse agonists identification.Therapeutic management of allergic diseases.Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.5-hydroxytryptamine subtype 6 receptor modulators: a patent survey.Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.CB1 receptor antagonists: new discoveries leading to new perspectives.Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors.The A, B, Cs of G-protein-coupled receptor pharmacology in assay development for HTS.Mechanistic analysis of the function of agonists and allosteric modulators: reconciling two-state and operational models.Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.Pharmacological Characterization of Human Histamine Receptors and Histamine Receptor Mutants in the Sf9 Cell Expression System.Constitutive Desensitization of Opioid Receptors in Peripheral Sensory Neurons.Shadows across mu-Star? Constitutively active mu-opioid receptors revisited.
P2860
Q24633892-E36CD666-CC4E-4E54-BBAF-EC6E1BE9BF16Q24671847-F9623F2D-B3BC-48F9-BAC6-DB5F68ABC6D1Q24675480-9A71AA2F-1B94-466C-810A-28FE53FCE1E9Q26782933-BDB484F7-0444-45E0-A97E-71C501D66FD3Q27005640-ABCEB3D2-E343-4E3C-8914-E11A2837633CQ33651029-66E1E58B-8951-44CD-A20E-A7B36140B238Q34451544-05CFE1D3-30F2-4151-AF13-DB055563AD1CQ34770179-62811C80-3A7E-4F94-894D-F452C88BC6E2Q35018179-CD01FCF2-6987-4787-AFE6-7B080A6D5F43Q35048967-80B50943-D312-4715-B135-F2A8CBC69AF5Q35049029-FAA68C0B-29CE-42FD-B588-EBFEF917C57FQ35216471-08DA939D-D4C7-4F1D-8671-76A70003583CQ35729971-0173A536-B6D9-4BDF-802A-8A49BD7E6705Q35980760-C19BA91C-F8D1-44A9-87E5-5AA45B6883F2Q36044310-8106F502-A7CD-4190-9D08-6716E9890315Q36054309-7B356EA6-1EE4-4C6B-96E1-C2563F53AD74Q36099400-F98E1ED0-69A6-4870-82C9-227D042038F7Q36259485-4437E0A9-24FA-48D6-8B1B-F5694A4D36A9Q36318560-9050998B-0C82-4465-8F23-5107FA185DAEQ36431626-46D2CD3E-4640-4E6F-BEB9-C5CB21D9EA5DQ36706667-9BF6D938-F018-463D-A61F-F1A90DD302D4Q36854402-3713A64F-CCE6-4816-B4B1-7B144C403FE9Q36911200-2BC6551D-50DD-4404-A12D-04DDA9C4F7C6Q37062556-770B4A02-4D95-4667-A62E-D45B339CC051Q37157903-C16A58A6-652B-4FD6-BD6E-BB34AD33C7A1Q37509443-57AF3649-C01D-4CBC-9058-FF95738F6FB9Q37548454-ABC5AFC8-25E7-4ACF-942B-DEDBC4E7CCB5Q37550543-BE05F731-CE88-486F-A6B0-93224F17EA56Q37776003-95188D8C-73E7-4961-A597-993FCCBF0A80Q37780550-6A411102-10CC-49CF-9578-5BA491127C99Q37862977-A8F9E7F5-C42C-4E43-BFC9-97860867040AQ37998561-26A0DD39-3795-4762-B841-57F14B70C22AQ38014954-24307EF8-0DAA-45AF-BFD0-14A8DAC42866Q38089142-6CB79C07-9CB3-49CA-BCBD-DDCA36D08861Q38104401-9F3DED6D-8303-4CF0-B58C-70EC86C9609AQ38209355-B0670CA9-1F9D-4644-BF03-2D9F98C667A6Q38810544-CF9845B7-A2B1-482F-B09E-F85A5659D7AFQ38944804-4188E1A4-A45F-47A5-8680-78A4372FDEFAQ39359627-E2A16AD5-75C1-49F9-AD73-950DA8A304F2Q39860832-D7073C65-4626-4D34-83A8-17E1C439D3E1
P2860
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
@ast
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
@en
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
@nl
type
label
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
@ast
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
@en
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
@nl
prefLabel
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
@ast
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
@en
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
@nl
P356
P1476
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
@en
P2093
Terry Kenakin
P356
10.1124/MOL.65.1.2
P577
2004-01-01T00:00:00Z